LncRNA <i>GAS5</i> alleviates rheumatoid arthritis through regulating miR-222-3p/Sirt1 signalling axis

Yang, Zhou; Lin, Shaomin; Zhan, Feng; Liu, Ying; Yang, Zhan

doi:10.1080/08916934.2020.1846183

Cited by 39 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased risk for complicating autoimmune diseases, such as systemic lupus erythematosus, autoimmune thyroid disease, and rheumatoid arthritis was observed in patients with MG (Nacu et al, 2015), indicating the existence of common pathological changes shared by these autoimmune disorders. It has been reported that lncRNA GAS5 is downregulated in rheumatoid arthritis and osteoarthritis (Yang et al, 2021;Zhang et al, 2021), and its down- , 2014). As an antiinflammatory factor (Ip et al, 2017), IL-10 was significantly inhibited in patients with MG (Sheng & Soliven, 2016).…”

Section: Discussionmentioning

confidence: 99%

LncRNA GAS5 positively regulates IL‐10 expression in patients with generalized myasthenia gravis

Peng

Huang

2021

Brain and Behavior

View full text Add to dashboard Cite

Introduction: LncRNA growth arrest-specific transcript 5 (GAS5) has been proven to be involved in autoimmune diseases. Rheumatoid arthritis is a type of autoimmune disease that may affect myasthenia gravis (MG) patients. However, its direct role in MG is unknown.Methods: Our study included 62 generalized MG patients. GAS5 expression was analyzed with real-time quantitative RT-PCR (qRT-PCR). The interaction between GAS5 and interleukin 10 (IL-10) was explored in overexpressed cells using real time quantitative polymerase chain reactions (RT-qPCRs) and western blot. The correlation of GAS5 and IL-10 was analyzed using Pearson's correlation analysis. The diagnostic value of GAS5 for MG was analyzed using receiver operating characteristic (ROC) curve analysis.Results: GAS5 and IL-10 mRNA levels in peripheral blood mononuclear cells (PBMCs) were significantly lower in MG patients than healthy controls. Downregulated GAS5 effectively distinguished MG patients from healthy controls. GAS5 expression was positively correlated with IL-10 expression in both MG patients and healthy controls.GAS5 overexpression significantly upregulated IL-10 expression in PBMCs derived from both MG patients and healthy controls. Conclusion:LncRNA GAS5 may improve generalized MG by positively regulating IL-10 expression.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNA GAS5 positively regulates IL‐10 expression in patients with generalized myasthenia gravis

Peng

Huang

2021

Brain and Behavior

View full text Add to dashboard Cite

show abstract

“…The lncRNA GAS5 is related to several autoimmune diseases. The expression of GAS5 in PBMCs and fibroblast-like synoviocytes (FLS) is lower in the serum of patients with RA (n=35) than that in normal controls (n=35) ( 92 , 93 ). Moreover, GAS5 can be used as a ceRNA to directly target miR-222-3p, upregulate the expression level of Sirt1, and inhibit the proliferation and inflammation of RA-FLS.…”

Section: Lncrna and Ramentioning

confidence: 98%

LncRNA Expression Profiles in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Emerging Biomarkers and Therapeutic Targets

Chen

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are two common multisystem autoimmune diseases that share, among others, many clinical manifestations and serological features. The role of long non-coding RNAs (lncRNAs) has been of particular interest in the pathogenesis of autoimmune diseases. Here, we aimed to summarize the roles of lncRNAs as emerging novel biomarkers and therapeutic targets in SLE and RA. We conducted a narrative review summarizing original articles on lncRNAs associated with SLE and RA, published until November 1, 2021. Based on the studies on lncRNA expression profiles in samples (including PBMCs, serum, and exosomes), it was noted that most of the current research is focused on investigating the regulatory mechanisms of these lncRNAs in SLE and/or RA. Several lncRNAs have been hypothesized to play key roles in these diseases. In SLE, lncRNAs such as GAS5, NEAT1, TUG1, linc0949, and linc0597 are dysregulated and may serve as emerging novel biomarkers and therapeutic targets. In RA, many validated lncRNAs, such as HOTAIR, GAS5, and HIX003209, have been identified as promising novel biomarkers for both diagnosis and treatment. The shared lncRNAs, for example, GAS5, may participate in SLE pathogenesis through the mitogen-activated protein kinase pathway and trigger the AMP-activated protein kinase pathway in RA. Here, we summarize the data on key lncRNAs that may drive the pathogenesis of SLE and RA and could potentially serve as emerging novel biomarkers and therapeutic targets in the coming future.

show abstract

“…As a competitive endogenous RNAs (ceRNA), lncRNA HIX003209 exaggerates inflammation through sponging miR-6089 via TLR-4/NF-kB pathway in RA macrophages (262). miR-222-3p/Sirt1 axis is also found to be critical for the function of lncRNA GAS5 in mitigating the proliferation, inflammation, and apoptosis of RA FLS (289). In particular, lncRNA NEAT1 and lncRNA HAND2-AS1 are found in PBMC and mesenchymal stem cells (MSC), respectively, and are involved in the regulation of RA (241,255).…”

Section: Epigenetic Targets For Treatment Of Rheumatoid Arthritismentioning

confidence: 98%

Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both existing and emerging targets, including the proteins, small molecular metabolites, and epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that result in inflammation and the development of new drugs for blocking the various modulators in RA.

show abstract

LncRNA GAS5 alleviates rheumatoid arthritis through regulating miR-222-3p/Sirt1 signalling axis

Cited by 39 publications

References 35 publications

LncRNA GAS5 positively regulates IL‐10 expression in patients with generalized myasthenia gravis

LncRNA GAS5 positively regulates IL‐10 expression in patients with generalized myasthenia gravis

LncRNA Expression Profiles in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Emerging Biomarkers and Therapeutic Targets

Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis

Contact Info

Product

Resources

About